NEW YORK (GenomeWeb News) – Sequenom and CombiMatrix today announced an agreement to market chromosomal microarray analysis testing services "to broaden and confirm the results of non-invasive prenatal testing" to doctors and patients.
Under the terms of the deal, the Sequenom Center for Molecular Medicine and CombiMatrix will promote the use of NIPD testing and CMA, as well as provide technical training to physicians. They also will provide counseling, educational, and support services to physicians and their patients, they said.
Additionally, the two companies plan to provide a comprehensive test result report for ordering physicians, when clinically appropriate.
Sequenom offers the MaterniT21 Plus test for trisomy 21, 18, and 13 and X and Y chromosomal material in cell-free DNA. In a statement, Sequenom President and COO Bill Welch said "for an important group of patients a chromosomal microarray test can be a significant adjunct for a comprehensive prenatal analysis. CombiMatrix specializes in CMA, and their technology helps further expand our product offering in the growing prenatal genetic testing marketplace."
Financial and other terms of the deal were not disclosed.
In Thursday morning trade on the Nasdaq, shares of CombiMatrix climbed 9 percent to $3.53, while Sequenom's stock was up a fraction of a percent at $3.02.